PMC:555537 / 14876-16163 JSONTXT

{"project":"2_test","denotations":[{"id":"15745441-10575906-9246013","span":{"begin":356,"end":358},"obj":"10575906"},{"id":"15745441-9920356-9246013","span":{"begin":356,"end":358},"obj":"9920356"},{"id":"15745441-10902065-9246013","span":{"begin":356,"end":358},"obj":"10902065"},{"id":"15745441-6959563-9246013","span":{"begin":356,"end":358},"obj":"6959563"},{"id":"15745441-7282596-9246013","span":{"begin":356,"end":358},"obj":"7282596"},{"id":"15745441-11144706-9246013","span":{"begin":356,"end":358},"obj":"11144706"},{"id":"15745441-9818800-9246013","span":{"begin":356,"end":358},"obj":"9818800"},{"id":"15745441-10674228-9246013","span":{"begin":356,"end":358},"obj":"10674228"},{"id":"15745441-7968059-9246013","span":{"begin":356,"end":358},"obj":"7968059"},{"id":"15745441-9621803-9246013","span":{"begin":356,"end":358},"obj":"9621803"},{"id":"15745441-10332534-9246013","span":{"begin":356,"end":358},"obj":"10332534"},{"id":"15745441-10575906-9246014","span":{"begin":675,"end":677},"obj":"10575906"},{"id":"15745441-9920356-9246014","span":{"begin":675,"end":677},"obj":"9920356"},{"id":"15745441-10902065-9246015","span":{"begin":993,"end":995},"obj":"10902065"},{"id":"15745441-6959563-9246015","span":{"begin":993,"end":995},"obj":"6959563"},{"id":"15745441-7282596-9246015","span":{"begin":993,"end":995},"obj":"7282596"}],"text":"Potential drug-BBT interactions\nExamination of patients' prescription and nonprescription medication profiles and BBT utilized, revealed 42 potential drug-BBT interactions. The onset of the interaction and the degree of severity were classified according to that used by the MicroMedex HealthCare Series Integraded Index [28] and the published literature [29-43]. Suspected or potential interactions were communicated to the patients and their primary physicians. The most common interaction identified was coadministration of aspirin and vitamin E (16 cases) that could potentially result in an increased risk of bleeding due to additive inhibition of platelet aggregation [29-31]. Similar effects may result from coadministration of clopidogrel and vitamin E; this potential interaction was recognized in five cases [31]. Five instances of potential interaction between warfarin and vitamin E were identified and close monitoring of the International Normalized Ratio (INR) was recommended [32-34]. A list of other potential drug-BBT interactions that were identified is presented in Table 4.\nTable 4 Potential Drug-Biological Based Therapies Interactions \u0026 Management INR = International Normalized Ratio\n* Delayed onset of interactions occurs after multiple doses of both agents.\n\n"}

{"project":"NEUROSES","denotations":[{"id":"T184","span":{"begin":10,"end":14},"obj":"CHEBI_23888"},{"id":"T185","span":{"begin":150,"end":154},"obj":"CHEBI_23888"},{"id":"T186","span":{"begin":1027,"end":1031},"obj":"CHEBI_23888"},{"id":"T187","span":{"begin":527,"end":534},"obj":"CHEBI_15365"},{"id":"T188","span":{"begin":596,"end":605},"obj":"PATO_0000470"},{"id":"T189","span":{"begin":735,"end":746},"obj":"CHEBI_37941"},{"id":"T190","span":{"begin":872,"end":880},"obj":"CHEBI_10033"},{"id":"T191","span":{"begin":964,"end":969},"obj":"PATO_0001038"},{"id":"T192","span":{"begin":964,"end":969},"obj":"PATO_0001470"}],"text":"Potential drug-BBT interactions\nExamination of patients' prescription and nonprescription medication profiles and BBT utilized, revealed 42 potential drug-BBT interactions. The onset of the interaction and the degree of severity were classified according to that used by the MicroMedex HealthCare Series Integraded Index [28] and the published literature [29-43]. Suspected or potential interactions were communicated to the patients and their primary physicians. The most common interaction identified was coadministration of aspirin and vitamin E (16 cases) that could potentially result in an increased risk of bleeding due to additive inhibition of platelet aggregation [29-31]. Similar effects may result from coadministration of clopidogrel and vitamin E; this potential interaction was recognized in five cases [31]. Five instances of potential interaction between warfarin and vitamin E were identified and close monitoring of the International Normalized Ratio (INR) was recommended [32-34]. A list of other potential drug-BBT interactions that were identified is presented in Table 4.\nTable 4 Potential Drug-Biological Based Therapies Interactions \u0026 Management INR = International Normalized Ratio\n* Delayed onset of interactions occurs after multiple doses of both agents.\n\n"}